Elgan Pharma Ltd.
- Address
- 13 Wadi El Haj
Sponsor Overview
Specializations
Neonatal gastroenterology
Elgan Pharma Ltd. focuses on intestinal malabsorption in preterm infants, with clinical research centered on digestive function in very early life and the challenges associated with immature intestinal absorption.
- Intestinal malabsorption
- Preterm infant nutrition
- Enteral feeding tolerance
The sponsor’s research activity also addresses the transition to full enteral feeding and the nutritional needs of infants with markedly limited gestational maturity.
Prematurity-related care
Its clinical portfolio includes infants born at extremely low gestational age and those with intrauterine growth restriction, reflecting a therapeutic interest in the medical complications associated with very early birth and impaired fetal growth.
- Extremely preterm birth
- Intrauterine growth restriction
- Postnatal growth support
These studies are aligned with the clinical management of infants at highest risk for nutritional instability and delayed gastrointestinal adaptation.
Pediatric safety evaluation
Elgan Pharma Ltd. also invests in pediatric safety assessment, with attention to tolerability and clinical monitoring in vulnerable neonatal populations receiving investigational support for gastrointestinal disorders.
- Safety assessment
- Neonatal tolerability
- Clinical monitoring
This area of interest extends to medically fragile infants requiring careful observation of feeding progression and digestive response.
Multinational neonatal research
The sponsor’s studies involve a broad network of collaborating sites across multiple countries, supporting research in neonatal medicine and pediatric nutrition within diverse clinical settings.
- Multicenter clinical research
- International neonatal care
- Pediatric clinical collaboration
This footprint indicates active engagement in cross-border clinical evaluation of therapies for infants with severe feeding and absorption difficulties.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy and Safety of ELGN-2112 in Treating Intestinal Malabsorption in Preterm Infants: A Double-Blind, Randomized, Placebo-Controlled Study |  Austria France Italy Spain Sweden The Netherlands | Recruiting |
| Safety Assessment of ELGN-2112 (Insulin Human) in Preterm Infants with Intestinal Malabsorption: A Double-Blind, Randomized, Placebo-Controlled Study | Austria France Italy Spain Sweden The Netherlands | Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 0 are not being studied by other sponsors.
This sponsor has worked with 25 sites across their trial portfolio.
Therapeutic Focus
- 1.Congenital, Hereditary, and Neonatal Diseases and Abnormalities2 trials165 other sponsors
Partnered Research Centres
25 centres- Address
- De Boelelaan 1117, 1081 HV Amsterdam
- Address
- Via Nicolo' Giustiniani 2, 35128 Padua
- Address
- Viale Luigi Borri N 57, 21100 Varese
- Address
- Residence Les Maisonnees, 10 Rue Du Champ Gaillard, 78300 Poissy
- Address
- 20 Rue Armagis, Bp 231, 78104 St Germain En Laye
- Address
- 4 Place Du Professeur Robert Debre, Bp 40026, 30029 Nîmes
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Elgan Pharma Ltd..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.